FDA approves the first myostatin inhibitor, a class GLP-1 muscle research has been watching

The Food and Drug Administration approved Isembyld (apitegromab-mstn) on September 11, 2026, for spinal muscular atrophy (SMA) in adults and children age 2 and older who are already taking a drug that targets the SMN2 gene ^[1][2]. Isembyld is a monoclonal antibody made by Scholar Rock that blocks myostatin, a protein that normally limits muscle growth ^[2]. It is the first drug in this class to win FDA approval, following what Scholar Rock's chief executive, David Hallal, called "decades of failed industry-wide efforts to unlock the potential of myostatin inhibition" ^[1][2].

The approval rests on the Phase 3 SAPPHIRE trial, a randomized, placebo-controlled study in patients already receiving an SMN2-targeted therapy. Adding Isembyld produced a 2.2-point improvement on the Hammersmith Functional Motor Scale-Expanded compared with SMN2 therapy alone after one year, in the main study group of 103 patients age 2 to 12 (nominal p = 0.0121) ^[2]. More than a third of patients on Isembyld, 34.2%, gained at least 3 points on that scale, versus 13.5% on placebo alone ^[2]. Patients on the SMN2-only regimen lost motor function over the same period, while those adding Isembyld improved ^[1][2].

The safety database covers more than 500 people across all apitegromab studies, some followed for more than seven years, and 98% of SAPPHIRE participants chose to continue into a long-term extension study ^[2]. The most common side effects were upper respiratory infections, vomiting, cough, other viral infections, headache, gastroenteritis, pharyngitis and hypersensitivity reactions ^[2]. Fractures occurred more often on the drug: 9% of patients on the 10 mg/kg dose had a fracture, compared with 2% on placebo ^[2]. Scholar Rock also received a Rare Pediatric Disease Priority Review Voucher tied to the approval ^[2].

Why it matters for patients

This approval is for spinal muscular atrophy, not for obesity or weight management, and Isembyld is not approved or being marketed as a companion to any GLP-1 medicine. Still, the news matters to people using or considering semaglutide (Ozempic, Wegovy, Rybelsus) or tirzepatide (Mounjaro, Zepbound) because it is the first time regulators have cleared any drug that works by blocking myostatin — the biological pathway several companies are studying as a way to protect muscle mass during GLP-1-driven weight loss. Losing lean muscle along with fat is a known concern with GLP-1 drugs, and this approval gives the myostatin mechanism a real-world safety and efficacy track record for the first time.

The sources reviewed for this article describe the SMA approval in detail but do not include specific results from a combination trial of apitegromab and tirzepatide in muscle preservation for weight loss. Readers should treat any claims about that combination as separate from what the FDA has actually reviewed and approved, since that data is not detailed in the sources here. What this approval does establish is that a myostatin inhibitor can clear FDA review, get real dosing and safety data (including the fracture signal seen in SAPPHIRE), and reach patients — a regulatory pathway other companies pursuing muscle-preserving GLP-1 add-ons will likely study closely.

What happens next

Scholar Rock said Isembyld would be available to ship within days of the approval and set up a patient support program to help with insurance and access questions ^[2]. The company held an investor call on September 14, 2026, to discuss the launch ^[2]. No timeline has been given in these sources for when, or whether, apitegromab or similar myostatin inhibitors might be tested or approved specifically for use alongside GLP-1 medicines for weight loss.